2. Neuronal Signaling
    Stem Cell/Wnt
  3. Notch

Notch

Notch

Related Products

PDF 0.58 MB

Notch signaling is evolutionarily conserved and operates in many cell types and at various stages during development. Notch signaling occurs via cell-cell communication, where transmembrane ligands on one cell activate transmembrane receptors on a juxtaposed cell.

Regulation of Notch signaling is critical to development and maintenance of most eukaryotic organisms. The Notch receptors (NOTCH1, 2, 3, and 4) and ligands (DLL1, 3, and 4, JAG1 and 2) are integral membrane proteins and direct cell-cell interactions are needed to activate signaling. Ligand-expressing cells activate Notch signaling through an unusual mechanism involving Notch proteolysis to release the intracellular domain from the membrane, allowing the Notch receptor to function directly as the downstream signal transducer.

Notch Related Products (59):

Cat. No. Product Name Effect Purity
  • HY-13027
    DAPT Inhibitor 99.91%
    DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].
  • HY-P1846A
    Jagged-1 (188-204) (TFA) Agonist 99.89%
    Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells[1][2][3].
  • HY-50752
    LY-411575 Inhibitor 99.33%
    LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with IC50 of 0.39 nM.
  • HY-10585
    Valproic acid Activator
    Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches[1][2][3][4][5][6][7].
  • HY-10585A
    Valproic acid sodium Activator
    Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches[1][2][3][4][5][6][7].
  • HY-120782A
    Yhhu-3792 hydrochloride Activator
    Yhhu-3792 hydrochloride enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 hydrochloride activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 hydrochloride expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 hydrochloride increases the spatial and episodic memory abilities of mice. Yhhu-3792 hydrochloride has the potential for the research of impairment of learning and memory associated DG dysfunction[1].
  • HY-131923
    DAPM Inhibitor
    DAPM is a Notch pathway inhibitor with anticancer activity and antiproliferative effects. DAPM effectively inhibits tubular adenoma development by inhibiting cell proliferation and inducing the expression of Krüppel-like factor 4 (KLF4) and p21 in human colon cancer cells[1].
  • HY-P990104
    Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) Inhibitor
    Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
  • HY-P1846
    Jagged-1 (188-204) Agonist
    Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells[1][2][3].
  • HY-P99043
    Rovalpituzumab Inhibitor
    Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine[1]. Rovalpituzumab has activity against small cell lung cancer (SCLC)[1].
  • HY-144899
    ASR-490 Inhibitor 99.05%
    ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice[1].
  • HY-10585S4
    Valproic acid-d4-1 Activator
    Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
  • HY-N0711
    Carvacrol Inhibitor 99.96%
    Carvacrol is an orally active monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates Notch-1, and Jagged-1, and induces apoptosis. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations[1][2].
  • HY-11102
    RO4929097 Inhibitor 98.89%
    RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively[1].
  • HY-10585AS
    Valproic acid-d7 sodium Activator
    Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
  • HY-N7028
    Withanolide A Inhibitor
    Withanolide A is an orally active extract from the Indian herb Ashwagandha. Withanolide A can induce apoptosis. Withanolide A has anti-inflammatory and antitumor activity. Withanolide A can be used in the study of neurodegenerative diseases[1][2][3][4].
  • HY-10585B
    Valproic acid (sodium)(2:1) Activator
    Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches[1][2][3][4][5][6][7].
  • HY-100431A
    IMR-1A Inhibitor 98.01%
    IMR-1A, a acid metabolite of IMR-1, is a Notch inhibitor with an IC50 of 0.5 μM. IMR-1A has a 50-fold increase in potency with respect to IMR-1. IMR-1 can metabolize in vivo to IMR-1A[1].
  • HY-145428
    BT-GSI Inhibitor
    BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression[1].
  • HY-50845
    Avagacestat Inhibitor
    Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.